Evolution of drug therapy in patients with resectable gastric and esophageal‑gastric junction cancer
Gastric cancer (GC) is the fifth most common malignant neoplasm in the world among all malignant tumors. Currently, the “gold” standard of treatment for patients with non‑metastatic cancer of the stomach and esophageal–gastric junction is surgical treatment, which is complemented by perioperative ch...
Saved in:
Main Authors: | M. V. Sedova, M. A. Batov, V. S. Tretyak, A. A. Kolomeytseva, V. M. Khomyakov, N. N. Volchenko, A. A. Fedenko, A. D. Kaprin |
---|---|
Format: | Article |
Language: | Russian |
Published: |
QUASAR, LLC
2023-06-01
|
Series: | Исследования и практика в медицине |
Subjects: | |
Online Access: | https://www.rpmj.ru/rpmj/article/view/920 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Safety assessment of preventive pressurized intraperitoneal aerosol chemotherapy in combined treatment of gastric cancer: preliminary results
by: N. Ya. Muratova, et al.
Published: (2024-03-01) -
Targeted therapy and immunotherapy for gastric cancer: rational strategies, novel advancements, challenges, and future perspectives
by: Dong Luo, et al.
Published: (2025-02-01) -
Comparative efficacy of programmed death ligand 1 inhibition and chemotherapy in advanced gastric or gastroesophageal junction cancer with combined positive score – a meta-analysis
by: Zakari Shaibu, et al.
Published: (2024-10-01) -
Dual-positive gastric cancer: an extremely malignant subtype of gastric cancer with high serum alpha-fetoprotein and carcinoembryonic antigen concentrations
by: Weixun Xie, et al.
Published: (2025-01-01) -
Invagination of the Adductor Loop of the Small Intestine into the Lumen of the Gastric Stump after Pancreatoduodenal Resection
by: G. V. Balitsky, et al.
Published: (2019-12-01)